Dupilumab: A review of its use in the treatment of atopic dermatitis
Top Cited Papers
- 1 March 2018
- journal article
- review article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 78 (3), S28-S36
- https://doi.org/10.1016/j.jaad.2017.12.022
Abstract
No abstract availableKeywords
Funding Information
- Bayer
- LEO Pharma
- Sanofi
This publication has 16 references indexed in Scilit:
- Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trialThe Lancet, 2015
- The translational revolution and use of biologics in patients with inflammatory skin diseasesJournal of Allergy and Clinical Immunology, 2015
- Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitisJournal of Allergy and Clinical Immunology, 2014
- Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approachesJournal of Allergy and Clinical Immunology, 2014
- Dupilumab Treatment in Adults with Moderate-to-Severe Atopic DermatitisNew England Journal of Medicine, 2014
- The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and AsthmaAllergy, Asthma & Immunology Research, 2011
- Eczema Prevalence in the United States: Data from the 2003 National Survey of Children's HealthJournal of Investigative Dermatology, 2011
- Therapeutic Protein–Drug Interactions and Implications for Drug DevelopmentClinical Pharmacology & Therapeutics, 2010
- Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activityJournal of Allergy and Clinical Immunology, 2001
- Effects of anti-IL-4 receptor monoclonal antibody onin vitroT cell cytokine levels: IL-4 production by T cells from non-atopic donorsClinical and Experimental Immunology, 1998